Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618696 · ClinicalTrials.gov registry record · Phase 1
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00618696 is a Phase 1 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 4 participants.
The verdict
NCT00618696, a Phase 1 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Radioactive monoclonal antibodies, such as yttrium Y 90 monoclonal antibody, can find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of a yttrium Y 90 monoclonal antibody and how much radiation is taken in by the organs in the body in treating patients with advanced leukemia or other hematologic disorder.
Interventions
- BIOLOGICAL anti-CD45 monoclonal antibody AHN-12
- RADIATION yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618696
The ClinicalTrials.gov registry entry for NCT00618696 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which anti-CD45 monoclonal antibody AHN-12 is the first listed.
NCT00618696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618696 about?
NCT00618696 is a clinical study titled "Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia". RATIONALE: Monoclonal antibodies can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Radioactive monoclonal antibodies, such as yttrium Y 90 monoclonal antibody, can find cancer cells and either kill them or carry cancer-killing substances to them wi...
What is the current status of trial NCT00618696?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2005-07. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00618696?
The interventions under investigation include: anti-CD45 monoclonal antibody AHN-12 (BIOLOGICAL), yttrium Y 90 anti-CD45 monoclonal antibody AHN-12 (RADIATION).
Who is sponsoring clinical trial NCT00618696?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.